Severe OHSS: Yes, there is a strategy to prevent it!

Human Reproduction

Volumn 15, Issue 11, 2000, Pages 2266-2267

  Kol, S ^a,b   Itskovitz Eldor, J ^b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

GnRH agonist; OHSS; Ovulation induction

Indexed keywords

GONADORELIN AGONIST; GONADORELIN ANTAGONIST; TRIPTORELIN;

HUMAN; INFERTILITY; NOTE; OVARY HYPERSTIMULATION; OVULATION INDUCTION;

FALLOPIA;

EID: 0033765009     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/15.11.2266     Document Type: Note

References (12)

1. Ethical issues on studies on the prevention of severe ovarian hyperstimulation syndrome
2. Severe OHSS: How many cases are preventable?
3. Severe OHSS - An acceptable price?
4. Preventing OHSS in at-risk patients: Evidence from a long-term prospective study
5. The induction of LH surge and oocyte maturation by GnRH analogue (buserelin) in women undergoing ovarian stimulation for in vitro fertilization
6. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist
7. Ovarian hyperstimulation syndrome after using gonadotrophin-releasing hormone analogue as a trigger of ovulation: Causes and implications
8. Triggering of preovulatory LH surge after treatment with the GnRH antagonist (Antagon) in IVF cycles and the prevention of ovarian hyperstimulation syndrome (OHSS)
9. The use of GnRH analogs for induction of the preovulatory gonadotropin surge in assisted reproduction and prevention of the ovarian hyperstimulation syndrome
10. Comparison of GnRH analogues and HCG for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: A case-control study
11. Counselling patients undergoing controlled ovarian stimulation about the risks of ovarian hyperstimulation syndrome
12. Triggering of ovulation using a gonadotrophin-releasing hormone agonist does not prevent ovarian hyperstimulation syndrome